A share price of Sarepta Therapeutics Inc [SRPT] is currently trading at $142.85, up 1.56%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SRPT shares have lost -0.13% over the last week, with a monthly amount drifted -5.69%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Sarepta Therapeutics Inc [NASDAQ: SRPT] stock has seen the most recent analyst activity on July 29, 2024, when RBC Capital Mkts upgraded its rating to a Outperform but kept the price target unchanged to $182 for it. Previously, Citigroup downgraded its rating to Neutral on June 26, 2024, and elevated its price target to $176. On May 31, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $157 on the stock. RBC Capital Mkts downgraded its rating to a Sector Perform and decreased its price target to $142 on May 28, 2024. Oppenheimer upgraded its rating to a Outperform but $180 remained the price target by the analyst firm on May 14, 2024. BMO Capital Markets started tracking with a Outperform rating for this stock on January 31, 2024, and assigned it a price target of $170.
Sarepta Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $55.25 and $173.25. Currently, Wall Street analysts expect the stock to reach $169.53 within the next 12 months. Sarepta Therapeutics Inc [NASDAQ: SRPT] shares were valued at $142.85 at the most recent close of the market. An investor can expect a potential return of 18.68% based on the average SRPT price forecast.
Analyzing the SRPT fundamentals
Trailing Twelve Months sales for Sarepta Therapeutics Inc [NASDAQ:SRPT] were 1.40B which represents 63.10% growth. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at 0.02%, and Net Profit Margin reading is 0.01%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.02 and Total Capital is -0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 140.88 points at the first support level, and at 138.92 for the second support level. However, for the 1st resistance point, the stock is sitting at 144.63, and for the 2nd resistance point, it is at 146.42.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Sarepta Therapeutics Inc [NASDAQ:SRPT] is 4.05. Further, the Quick Ratio stands at 3.44, while the Cash Ratio is 0.7. Considering the valuation of this stock, the price to sales ratio is 9.62, the price to book ratio is 14.04 and price to earnings (TTM) ratio is 2148.12.
Transactions by insiders
Recent insider trading involved Brown Ryan Edward, EVP, General Counsel, that happened on Jun 25 ’24 when 38957.0 shares were sold. Chief Tech Ops Officer, Arif Bilal completed a deal on Jun 25 ’24 to sell 3898.0 shares. Meanwhile, Chief Tech Ops Officer Arif Bilal sold 7859.0 shares on Jun 24 ’24.
